profit from every $100 of sales.
$0$100
Anika Therapeutics
$13.47-7.55% today
+33.8% in 1 year
1-year low $9.131-year high $22.03
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Anika Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $114 million in 2022 to $113 million in 2025, with -$10.9 million of profit last year.
SalesProfit
Anika Therapeutics handed back more cash to shareholders than it generated last year.
Buybacks $9M
Free cash flow 2025$4M
Bought back its own shares$9M
Paid as dividends–
Cash vs. debt$57M vs. $26M
Anika Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Anika Therapeutics | No profit yet | ||
 Boston Scientific | 22.4× · Fair price | ||
 Koninklijke Philips | 29.7× · Fair price | ||
 Steris | 31.9× · Expensive | ||
 Zimmer Biomet Holdings | 28.8× · Fair price |
AI analysis
An AI analyst reads Anika Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 114 | 121 | 120 | 113 | |
| 73 | 83 | 76 | 64 | |
| 4 | 1 | -5 | -11 | |
| 18 | 15 | 3 | -5 | |
| -15 | -83 | -56 | -11 | |
| -1.02 | -5.64 | -3.83 | -0.76 | |
| 64.3% | 68.3% | 63.4% | 56.6% | |
| 3.2% | 0.7% | -4.3% | -9.8% | |
| -13.1% | -68.4% | -47.0% | -9.6% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 349 | 271 | 203 | 190 |
| Cash | 86 | 69 | 56 | 57 |
| Total debt | 31 | 28 | 26 | 26 |
| Total liabilities | 64 | 58 | 49 | 47 |
| 286 | 212 | 154 | 143 | |
| 15 | 15 | 15 | 14 | |
| 0.9% | 0.3% | -2.2% | -5.1% | |
| -5.2% | -38.9% | -36.6% | -7.6% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 4 | -2 | 5 | 11 | |
| 7 | 5 | 8 | 7 | |
| -3 | -7 | -3 | 4 | |
| Dividends paid | – | – | – | – |
| 0 | 5 | 11 | 9 | |
| 14 | 15 | 13 | 10 |
Valuation
- –
- –
- –
- 1.5×
- 1.6×
- 41.4×
- –
- 2.4%
- -6.0%
- 0.0%
Profitability
- 56.6%
- -9.8%
- -9.6%
- -5.7%
- -7.6%
- -15.1%
- -7.7%
- -6.2%
- -7.7%
- 22.7%
Growth
- −0.3%
- –
- +287.1%
- –
- −0.1%
Financial health
- -5.9×
- 0.19
- 14.3%
- –
- 4.46
- 3.37
- 0.65
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 29%of 953
Bottom 16%of 877
Bottom 15%of 871
Top 38%of 988
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 29, 2026 | 0.27 | -0.07 | +485.7% |
| Feb 26, 2026 | 0.31 | -0.13 | +348.0% |
| Nov 5, 2025 | 0.04 | 0.02 | +100.0% |
| Jul 30, 2025 | -0.13 | -0.13 | +0.0% |
| May 9, 2025 | -0.06 | 0.09 | −166.7% |
| Mar 12, 2025 | -0.03 | -0.01 | −200.0% |
| Oct 31, 2024 | -0.25 | 0.30 | −183.3% |
| Aug 8, 2024 | 0.17 | 0.23 | −26.1% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
30No pass
Benjamin Graham
59No pass
Philip Fisher
34No pass
Peter Lynch
27No pass
Joel Greenblatt
0No pass
Charlie Munger
34No pass
Terry Smith
25No pass
Questions about Anika Therapeutics
Is Anika Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Anika Therapeutics AI analysis
What does Anika Therapeutics do?
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. It is in Medical - Devices.
Does Anika Therapeutics pay a dividend?
No. Anika Therapeutics does not pay a dividend at the moment; in 2025 it returned $9.49 million to shareholders by buying back its own shares.
Is Anika Therapeutics stock halal?
Questionable. Anika Therapeutics sits in a grey zone: its cash and confirmed interest-bearing investments are 32% of its market value, between 30% and 33%. How we check
How has Anika Therapeutics stock done over the past year?
Up 33.8% over the past twelve months, to $13.47. It traded between $9.13 and $22.03 and is 38.9% below its high.
Who are Anika Therapeutics's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Steris and Zimmer Biomet Holdings. The peers table on this page compares their profit, growth and price with Anika Therapeutics's.
Prices: daily closes to Nov 10, 2026. Fundamentals: company reports via invest-like data.